0HI3.LSE Arrowhead Pharmaceuticals Corp.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -84.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 0HI3.LSE undervalued?
Graham numberThe Graham number of Arrowhead Pharmaceuticals Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arrowhead Pharmaceuticals Corp. fundamental analysis
No fundamental analysis for Arrowhead Pharmaceuticals Corp. yet.
Arrowhead Pharmaceuticals Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arrowhead Pharmaceuticals Corp.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also …
Full company profileArrowhead Pharmaceuticals Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arrowhead Pharmaceuticals Corp. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 158K | 31.4M | 16.1M | 169M | 88.0M | 138M | 243M | 241M | 3.55M | 829M | 551M |
| Gross Profit | 158K | 31.4M | 16.1M | 169M | 88.0M | 138M | 233M | 228M | -15.0M | 806M | 525M |
| Operating Income | -85.6M | -37.0M | -55.9M | 61.2M | -93.2M | -149M | -179M | -205M | -601M | 98.3M | -361M |
| EBITDA | -82.3M | -29.7M | -51.2M | 72.6M | -78.6M | -133M | -168M | -193M | -562M | 165M | -322M |
| Net Income | -81.7M | -34.4M | -54.5M | 68.0M | -84.6M | -141M | -176M | -205M | -599M | -1.63M | -395M |
| EPS | -1.34 | -0.47 | -0.65 | 0.69 | -0.84 | -1.36 | -1.67 | -1.92 | -5.00 | -0.01 | -2.75 |
| Balance Sheet | |||||||||||
| Total Assets | 128M | 104M | 112M | 350M | 523M | 710M | 692M | 766M | 1.14B | 1.45B | 2.11B |
| Total Liabilities | 33.2M | 23.2M | 16.4M | 106M | 60.7M | 301M | 274M | 478M | 949M | 947M | 1.65B |
| Shareholders' Equity | 95.6M | 81.4M | 95.8M | 245M | 462M | 409M | 399M | 271M | 185M | 466M | 466M |
| Cash & Short-term Investments | 85.4M | 65.6M | 76.5M | 259M | 315M | 368M | 376M | 396M | 681M | 919M | 1.60B |
| Total Debt | 2.73M | 2.53M | 2.33M | - | 21.1M | 25.5M | 81.6M | 383M | 852M | 734M | 1.38B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -64.4M | -23.9M | -47.2M | 173M | -95.4M | 171M | -136M | -154M | -463M | 180M | -131M |
| Capital Expenditure | 3.86M | 7.92M | 1.42M | 12.0M | 12.0M | 23.6M | 52.8M | 177M | 141M | 22.7M | 11.4M |
| Free Cash Flow | -68.3M | -31.9M | -48.6M | 161M | -107M | 148M | -189M | -331M | -604M | 157M | -142M |
| Ratios | |||||||||||
| ROE | -85.5% | -42.2% | -56.8% | 27.8% | -18.3% | -34.5% | -44.2% | -75.7% | -323.3% | -0.3% | -84.8% |
| ROA | -63.8% | -33.1% | -48.8% | 19.4% | -16.2% | -19.8% | -25.4% | -26.8% | -52.6% | -0.1% | -18.7% |
| Net Profit Margin | -51,614.6% | -109.5% | -337.3% | 40.3% | -96.1% | -101.9% | -72.4% | -85.3% | -16,882.4% | -0.2% | -71.7% |
| Debt to Equity | 0.03x | 0.03x | 0.02x | - | 0.05x | 0.06x | 0.20x | 1.41x | 4.59x | 1.57x | 2.96x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arrowhead Pharmaceuticals Corp. dividends
Arrowhead Pharmaceuticals Corp. has not paid dividends in the last 9 fiscal years.
Who owns Arrowhead Pharmaceuticals Corp.
- Insiders 3.66%
- Institutions 85.37%
- Public & others 10.98%
- Free float 122M
Arrowhead Pharmaceuticals Corp. company profile
- Company name
- Arrowhead Pharmaceuticals Corp.
- Ticker
- 0HI3.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 711
- Fiscal year end
- September
- Address
- 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
- Phone
- 626 304 3400
- Website
- arrowheadpharma.com
About Arrowhead Pharmaceuticals Corp.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals Corp. management
10- Dr. Christopher R. Anzalone Ph.D.Chairman, CEO & President · born 1969
- Mr. Daniel J. ApelChief Financial Officer · born 1966
- Mr. Patrick O'Brien J.D., PharmDCOO & Secretary · born 1964
- Dr. James C. Hamilton M.D., MBAChief Medical Officer and Head of R&D · born 1979
- Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & Calando
- Dr. Tao Pei Ph.D.Chief Scientific Officer
- Dr. Vincent Anzalone CFAHead of Investor Relations & VP
- Mr. Howard LovyDirector of Communications
- Dr. Bruce D. Given M.D.Chief Medical Scientist · born 1954
- Dr. Mark SeefeldHead of Toxicology & VP · born 1954